HALO241220P75000
- 30.20
- 0.000.00%
Halozyme Therapeutics Newsroom
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
Trending: Halozyme Drops Bid for Evotec
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why
Express News | Evotec Confirms Review Of Halozyme's Withdrawn EUR 11.00/Share Proposal, Reiterates Confidence In Standalone Growth Strategy
Express News | U.S.-Listed Shares of Evotec Down 19.8% Premarket
Sector Update: Health Care Stocks Advance Premarket Friday
Sector Update: Health Care
Halozyme Therapeutics Shares Are Trading Higher After the Company Announced It Withdrew Plans to Acquire Evotec.
Halozyme Therapeutics Well-positioned to Execute Existing Strategy With Clear Line of Sight to 10 Approved Products With ENHANZE in 2025 and $1B of Royalty Rev in 2027 >HALO
Express News | Halozyme Therapeutics Inc: Reiterate Raised 2024 Guidance for Revenue of $970-$1,020 Mln and Adjusted Ebitda of $595-$625 Mln
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $68
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
HALO Vs. FOLD: Which Stock Should Value Investors Buy Now?
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $73
Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?
Evotec Plunges Amid Report It's Against Halozyme Therapeutics Takeover
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $62
Halozyme Says EUR2 Billion Takeover of Evotech Would Create Leader in Drug Discovery
Express News | Halozyme Therapeutics Inc - All-Cash Transaction Funded by Cash and New Debt